Tesamorelin: The GHRH Analogue With Real Phase 3 Data

Tesamorelin is the odd one out in the growth hormone peptide category, and the reason is simple. It has an approval. While sermorelin, CJC-1295, ipamorelin and the rest circulate on forum protocols and vendor claims, tesamorelin went through randomised placebo controlled phase 3 trials with a hard imaging endpoint, and a regulator looked at the result and said yes.

That does not make it better for every goal, and it does not make it safe to use casually. It does mean that when someone asks what a growth hormone releasing peptide actually does to human body composition, tesamorelin is the only compound in the class that answers with trial data rather than anecdote. This page covers the mechanism, what the trials measured, the limits nobody advertises, and how it compares with the cheaper alternatives.

What Tesamorelin Actually Is

Tesamorelin is a synthetic analogue of human growth hormone releasing hormone, the 44 amino acid signal the hypothalamus sends to the pituitary to trigger a growth hormone pulse. Native GHRH is fragile, cleared within minutes by the enzyme dipeptidyl peptidase 4. Tesamorelin carries a trans-3-hexenoyl group attached to the N-terminus, a modification whose only job is to blunt that enzymatic attack and keep the molecule intact long enough to do something.

The consequence is the whole argument for GHRH analogues over injected growth hormone. Tesamorelin does not put growth hormone into the body. It asks the pituitary to release its own, so the release stays pulsatile and the feedback loops running through somatostatin and IGF-1 stay intact. If the system has had enough, it can say so. Exogenous growth hormone overrides that conversation entirely.

It reached the market as Egrifta, developed by Theratechnologies and approved by the FDA in November 2010 for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. Later formulations cut the reconstitution burden and the daily dose, but the indication never widened. Every other use sits outside the label.

The Visceral Fat Question

HIV associated lipodystrophy produces an unusual fat distribution problem. Older antiretroviral regimens drove an accumulation of visceral adipose tissue, the fat packed around the organs inside the abdominal wall, often alongside a loss of fat under the skin. Visceral fat is the metabolically dangerous depot, tied to insulin resistance and cardiovascular risk in a way subcutaneous fat is not, and it responds poorly to diet and exercise here.

Growth hormone is strongly lipolytic and acts with particular force on visceral adipose tissue, which carries a higher density of growth hormone receptors than subcutaneous fat. That is the mechanistic bet behind tesamorelin. Raise endogenous growth hormone into the upper physiological range and the tissue most responsive to it is the tissue you most want to lose.

The phase 3 programme tested that bet across two multicentre randomised placebo controlled trials, dosing 2 mg subcutaneously once daily for 26 weeks with visceral adipose tissue measured by CT. Pooled, tesamorelin reduced visceral fat by roughly 15 to 18 percent relative to placebo. IGF-1 rose substantially, triglycerides improved, and total body weight moved very little.

That last detail is the one to hold onto. This is not a weight loss drug and does not behave like one. It relocates and reduces a specific fat depot without producing the scale movement people expect from the GLP-1 class. Anyone comparing tesamorelin with semaglutide or tirzepatide on pounds lost is comparing two drugs that were never trying to do the same thing.

The Part That Is Rarely Advertised

The trials included an extension in which some participants were switched from tesamorelin to placebo. Over the following six months their visceral fat came back, drifting toward baseline. The benefit is maintained only while dosing continues.

This is the most commercially awkward fact about the compound and the one most often missing from vendor pages. Tesamorelin is not a course you run to reset body composition. It is a maintenance therapy, and a twelve week protocol is not a cheaper version of the same result, it is a temporary one.

Response was also uneven. A meaningful minority of trial participants showed little visceral fat change, and the pooled averages hide that spread, which is why clinical guidance settled on reassessing after several months rather than assuming the drug is working because it is being injected.

Liver Fat and the Research That Followed

The most interesting work after approval looked at the liver. Since visceral adiposity and hepatic steatosis travel together, researchers asked whether tesamorelin would pull fat out of liver tissue as well. Studies in people with HIV and fatty liver, using MRI to measure hepatic fat fraction, reported clear reductions, with a share of participants falling below the threshold that defines steatosis.

That is why tesamorelin keeps appearing in metabolic research discussion. It is also narrower than it gets reported. The work was done in one population with a specific driver of liver fat, the trials were modest in size, and no regulator has approved tesamorelin for fatty liver disease in anyone.

How It Compares With the Cheaper GH Peptides

Most people asking about tesamorelin are really asking whether it is worth the price gap over the alternatives. The honest answer depends on which alternative, because they are not all doing the same thing.

The pattern is straightforward. GHRH analogues and ghrelin receptor agonists pull the same lever from two different directions, which is why CJC-1295 and ipamorelin are so often run together. Tesamorelin sits in the GHRH column, and what separates it from its neighbours is not a novel mechanism but the fact that someone paid for the trials. Our sermorelin versus GHRP-6 comparison and the MK-677 guide cover the other side of that split in detail.

Side Effects and Who Should Not Touch It

Most of what showed up in trials is recognisable as growth hormone excess in miniature, which is what it is.

• Fluid retention effects. Swelling in the hands and feet, joint pain, muscle pain, and tingling or numbness in the extremities. These cluster early and often settle, and they are the classic signature of raised growth hormone.
• Injection site reactions. Redness, itching and irritation were among the most frequently reported complaints, unsurprising for a daily subcutaneous injection.
• Glucose handling. Growth hormone opposes insulin. Fasting glucose and insulin sensitivity can worsen, which matters most in exactly the population carrying visceral fat in the first place.
• IGF-1 elevation. Expected, since it is the mechanism working, but it needs monitoring rather than celebrating.

The contraindications are firmer than the side effects. Active malignancy is an absolute one, because growth hormone and IGF-1 are growth signals and nobody wants to accelerate an existing tumour. Pregnancy is another, as is disrupted pituitary function from surgery, radiation or trauma, since a drug that asks the pituitary to release growth hormone needs a pituitary capable of answering. Anyone with a history of cancer, diabetes or retinopathy is in territory that requires a clinician rather than a forum. The broader picture is in our peptide side effects guide.

Practical Handling

Tesamorelin ships lyophilised and is reconstituted before subcutaneous abdominal injection, once daily, with sites rotated to limit the reactions that dominate the complaint list. Dosing has changed across formulations, and the specifics belong in our tesamorelin dosage guide.

Two handling points are worth flagging because they quietly destroy results. Peptides are sensitive to heat, light and agitation, and a vial reconstituted carelessly or stored at the wrong temperature can lose potency without any visible sign. Someone concluding the compound does not work may only have established that their handling does not. Our reconstitution guide and storage guide cover both, and the injection mechanics are in the injection guide.

The second is verification. Material obtained outside a pharmacy has no chain of custody, and a lyophilised white powder looks identical whether it is the right peptide, the wrong one or mostly mannitol. Third party testing is the only way to know.

Where Tesamorelin Genuinely Fits

Strip away the marketing and the case is narrow but real. Tesamorelin is the answer when the target is visceral adipose tissue specifically, confirmed through imaging rather than assumption, and when continuous dosing is acceptable because the effect stops when the drug does.

It is the wrong tool for general weight loss, where the GLP-1 and GIP agonists are dramatically more effective, an expensive way to chase sleep or recovery, and a poor choice for anyone whose actual problem is subcutaneous fat, because that is not the tissue it acts on. If the goal is general fat loss, the fat loss peptide comparison is the better starting point.

Key Takeaways

• Tesamorelin is a stabilised GHRH analogue that triggers the pituitary to release its own growth hormone, keeping the pulse pattern and feedback loops intact
• It is the only compound in the growth hormone peptide category with phase 3 trials and an FDA approved indication behind it
• Trials showed roughly 15 to 18 percent visceral fat reduction against placebo over 26 weeks, with almost no change in total body weight
• The visceral fat returns after discontinuation, which makes it a maintenance therapy rather than a course
• Liver fat findings are promising but come from one specific population and support no approval
• Side effects track growth hormone excess, and active malignancy, pregnancy and pituitary dysfunction are hard contraindications
• For general weight loss it is the wrong drug and the GLP-1 class is not a close contest

Frequently Asked Questions

What is tesamorelin used for?

Tesamorelin holds one approved indication, the reduction of excess abdominal fat in people with HIV associated lipodystrophy, granted by the FDA in 2010 under the brand name Egrifta. Everything else it is used for, including general visceral fat reduction, liver fat reduction and anti-ageing protocols, is off label or investigational. It is not approved as a general weight loss drug and does not behave like one.

How much visceral fat does tesamorelin remove?

In the phase 3 programme, 26 weeks of daily tesamorelin reduced visceral adipose tissue by roughly 15 to 18 percent relative to placebo, measured by CT rather than by weight or tape. Total body weight barely moved, because the compound shifts fat from a specific depot rather than creating a large energy deficit. Individual response varied widely, and a subgroup saw little change at all.

Does visceral fat come back after stopping tesamorelin?

Yes. Trial participants who were switched from tesamorelin to placebo after 26 weeks regained visceral fat over the following six months, returning toward their starting point. The effect depends on continuous dosing, which is the single most commercially inconvenient fact about the drug and the one most often left out of vendor copy.

How is tesamorelin different from sermorelin or CJC-1295?

All three act on the same GHRH receptor, but tesamorelin is the only one taken through phase 3 trials with a hard imaging endpoint. Sermorelin is a shorter GHRH fragment with a very brief half life, and CJC-1295 is a modified fragment engineered for longer action. Ipamorelin and MK-677 are not GHRH analogues at all, working instead through the ghrelin receptor.

What are the main tesamorelin side effects?

The recurring ones in trials were injection site reactions, joint pain, muscle pain, swelling in the hands and feet, and tingling or numbness consistent with mild fluid retention. Blood glucose and insulin sensitivity can worsen, since growth hormone opposes insulin. Tesamorelin is contraindicated in active malignancy, in pregnancy, and in people with disrupted pituitary function.

Does tesamorelin reduce liver fat?

Studies in people with HIV and fatty liver reported meaningful reductions in hepatic fat fraction on MRI, with a share of participants dropping below the threshold for steatosis. That work is genuinely interesting but was done in one specific population, and tesamorelin is not approved for fatty liver disease in anyone. Treating it as an established liver therapy overstates what has been shown.